Last reviewed · How we verify
Multiple administration Emg dose group
At a glance
| Generic name | Multiple administration Emg dose group |
|---|---|
| Sponsor | J2H Biotech |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males (PHASE1)
- Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers (PHASE1)
- Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease (PHASE4)
- Effect of Phototherapy in Individuals With Temporomandibular Disorder. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multiple administration Emg dose group CI brief — competitive landscape report
- Multiple administration Emg dose group updates RSS · CI watch RSS
- J2H Biotech portfolio CI